Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes
Open Access
- 1 August 2008
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (8), 1629-1634
- https://doi.org/10.2337/dc08-0371
Abstract
OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS—Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18–0.65], P = 0.0012 unadjusted, and 0.35 [0.18–0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS—ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population.Keywords
This publication has 29 references indexed in Scilit:
- Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 DiabetesJournal of the American Society of Nephrology, 2006
- Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidneyProceedings of the National Academy of Sciences of the United States of America, 2006
- The renin–angiotensin–aldosterone system, glucose metabolism and diabetesTrends in Endocrinology & Metabolism, 2005
- Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus AtenololCirculation, 2003
- Blood Pressure–Independent Attenuation of Cardiac Hypertrophy by AT 1 R-AS Gene TherapyHypertension, 2002
- American Heart JournalAnnals of Noninvasive Electrocardiology, 2001
- The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literatureArchives of Internal Medicine, 1997
- Differential regulation of vascular angiotensin I-converting enzyme in hypertension.Hypertension, 1994
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyThe New England Journal of Medicine, 1990
- Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension Detection and Follow-up Program Cooperative Group.Hypertension, 1985